The global Transfusion Diagnostics Market is expected to grow at a high CAGR of 6.2% during the forecasting period (2022-2029).
Blood transfusion is the process of transferring blood to the body. Transfusions are used for various medical conditions to replace lost components of the blood.
Blood transfusions are done to replace blood lost during surgery or due to a severe injury. A transfusion also may be done if the body can’t make blood properly because of an illness.
Blood transfusions are very common; almost Five million people receive a blood transfusion every year in the U.S.
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/transfusion-diagnostics-market
The rising prevalence of blood cancer is one of the factors fueling the global transfusion diagnostics market.
According to the Leukemia Research Foundation, in 2018, more than 201,870 new cases of blood cancer are expected in the United States. Approximately 387,000 Americans are living with leukemia.
According to Cancer Research UK, there are around 9,900 new leukemia cases in the UK every year. Leukemia is the 12th most common cancer in the UK, accounting for 3% of all new cancer cases. In 2015, leukemia became 10th most common cancer in males with around 5,900 new cases in U.K, and 12th most common cancer in the female, with approximately 4,000 new cases in U.K.
- Instruments & Kit
- Blood grouping
- Disease screening
The regulatory approval, a strategic alliance between companies and the launch of new diagnostics, is one of the critical factor driving the global transfusion diagnostics market.
In January 2019, Immucor, Inc., a global leader in transfusion and transplantation diagnostics, has received approval by Health Canada for its fully automated Echo instrument, Echo Lumena, designed for the small to mid-volume laboratory segment, is Immucor’s fifth-generation immunohematology instrument and brings brilliant performance and more unambiguous test results.
In June 2017, Grifols, and Beckman Coulter Inc. entered into an exclusive, long-term agreement for the global distribution of Grifols’ hemostasis instruments, reagents, and consumables.
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions.